Valuation: Evotec SE

Market Cap 492M 551M 458M 416M 786M 53.32B 789M 5.51B 2.16B 27.18B 2.07B 2.02B 87.23B P/E 2026 *
-2.17x
P/E 2027 * -6.43x
Enterprise Value 635M 711M 591M 537M 1.01B 68.8B 1.02B 7.11B 2.79B 35.07B 2.67B 2.61B 113B EV / Sales 2026 *
1.06x
EV / Sales 2027 * 0.9x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week-5.21%
Current month-10.71%
1 month-9.07%
3 months-44.04%
6 months-38.90%
Current year-49.21%
1 week 2.77
Extreme 2.768
3.12
1 month 2.71
Extreme 2.71
3.14
Current year 2.71
Extreme 2.71
6.73
1 year 2.71
Extreme 2.71
7.3
3 years 2.71
Extreme 2.71
21.69
5 years 2.71
Extreme 2.71
45.47
10 years 2.71
Extreme 2.71
45.83
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Exercice

Chief Technology Officer

12,462 0.0070%
5/4/26 Buy 15,510 0.0087%
5/4/26 Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-5.21%-58.67%-84.52% 551M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.61%-2.91%+38.79%+91.43% 37.71B
Weighted average by Cap. +0.56%-2.95%+51.19%+115.28%

Financials

2026 *2027 *
Net sales 601M 673M 559M 508M 960M 65.12B 964M 6.73B 2.64B 33.2B 2.53B 2.47B 107B 724M 811M 674M 613M 1.16B 78.47B 1.16B 8.11B 3.18B 40.01B 3.04B 2.98B 128B
Net income -222M -249M -207M -188M -355M -24.06B -356M -2.49B -974M -12.26B -933M -913M -39.36B -48.25M -54.03M -44.88M -40.83M -77.09M -5.23B -77.42M -540M -212M -2.67B -203M -198M -8.55B
Net Debt 143M 160M 133M 121M 228M 15.48B 229M 1.6B 627M 7.89B 601M 588M 25.33B 162M 182M 151M 137M 259M 17.57B 260M 1.82B 711M 8.96B 682M 667M 28.75B
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
26-10-09 €2.768 -1.35% 782,994
26-10-08 €2.806 -4.36% 1,181,049
26-10-07 €2.934 -0.14% 1,241,090
26-10-06 €2.938 -0.81% 923,177
26-10-05 €2.962 +1.44% 705,789
Trader
Investor
Global
Quality
ESG MSCI
AAA
Ratings Surperformance© - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.768EUR
Average target price
4.586EUR
Spread / Average Target
+65.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE